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Book Reviews
Lung Cancer Differentiation. Implications for Diagnosis and
Treatment
Edited by S.D. Bernal & P.J. Hesketh, New York: Marcel
Dekker, 1993, 302pp. $175.00.
The term 'differentiation' is used in biology and pathology to
describe the qualitative changes involved in the process of
cell specialisation. The term is not defined in this book,
which purports to be a monograph on the biology and
clinical implications of differentiation in lung cancer. What
the volume is, in fact, is a diverse collection of essays on a
whole range of biological and clinical aspects of pulmonary
neoplasia ranging from the role of the extracellular matrix in
cell differentiation to an evaluation of population-based
screening for the early detection of lung cancer. Some
chapters (for example those on the epidermal growth factor
receptor and on small-cell lung cancer antigens) are useful,
well written and up to date, but the book suffers badly from
a lack of direction and there are some glaring omissions. A
most striking example is a complete lack of discussion of
lung tumour histological classification, which is based
entirely on morphological assessment of cell differentiation.
The WHO classification of lung cancer is not even rep-
roduced in tabular form. Other areas poorly covered include
non-small-cell lung cancer differentiation markers (involucrin
is referred to only once for example) and, in the clinical
section, the role of surgical resection in the various his-
tological subtypes of lung cancer.
An introductory chapter providing an overview of the
biology of differentiation and the particular problems of lung
cancer might have addressed some of these deficiencies.
Overall, therefore, the book is poorly edited and does not
adequately cover the remit suggested in its title. It would be
difficult to justify recommending its purchase.
F.A. Carey
Progress and Perspectives in Chemoprevention of Cancer
Seroni Symposia Publications, Vol. 79
Edited by G. de Palo, M. Sporn & U. Veronesi, New York:
Raven Press, 1993, 316 pp. $139.00.
This book is volume 79 in the series of Serono Symposia. I
am ashamed to say that I have missed the first 78 so it is
difficult for me to place the book in context! It would appear
however to be a book of a 'meeting' that was held in Milan
in March 1991, so it is 21 years out of date. The Gulf War
coincided with the conference and therefore a number of
potential participants did not actually make it to Milan.
The basic material is fairly comprehensive and has not
suffered from the passage of time. De Flora and his col-
leagues from Genoa have written an excellent introductory
chapter describing various mechanisms of action and interac-
tion of agents used in cancer chemoprevention, and Moon,
who could be seen as the Virchow of this area of pathology,
contributes his usual lucid description of the activity of
retinoids on experimental mammary cancer. There are a
number of other short papers on mechanisms of various
agents, the best being by Jordan, who was one of the first
experimental pathologists to realise that tamoxifen had
potential as a chemosuppressive agent. The clinical studies,
which include the pharmacology of some of the drugs in use,
are dominated by the Milan group, and rightly so as it
reflects their dominant position in this area of clinical
oncological research.
Another substantial contribution, historically, has been
made by Hong of the M.D. Anderson hospital. He has
organised and reported on a series ofwell-thought-out logical
trials in the area of head and neck cancers, including cancers
of the mouth. At least three of his trials have reached the
giddy heights of publication in the New England Journal of
Medicine, and he was the first to use the extremely cost-
effective model of successfully treated lung and head and
neck cancer patients for testing potential chemopreventive
agents. He argued persuasively that the biggest risk factor for
lung cancer is previous lung cancer, just as is the case for
contralateral breast cancer following breast cancer. He was
also the first to report that mortality and second smoking-
related cancers in the aerodigestive tract are legitimate end-
points for this kind of study. The recent clinical trial from
the Royal Marsden by Powles et al. is presented in embryo
form. The full report has now been published elsewhere.
The main drawback with this book is that it is based on a
conference 21 years ago and there is still no real evidence that
scientists and clinicians outside the authorship of this book
have taken up the standard and followed in the crusade.
There have been a number of meetings on chemopreven-
tion in the last 3 or 4 years, and sadly it tends to be the same
faces and the same presentations given at each of them. It is
not surprising, therefore, to find some of these articles in
different forms in other symposia proceedings. Overall, how-
ever, it is a nicely produced book, and for a newcomer to the
area ofchemoprevention a comprehensive introduction to the
key issues and the key players.
J.G. McVie
The Carcinogenicity Debate
Edited by J.A.N. McAuslane, C.E. Lunley & S.R. Walker,
Lancaster: Quay Publishing, 1992, 302 pp. £49.95.
Carcinogenicity testing is a vexed topic for many reasons.
This book, however, concentrates on the test itself, its
validity and prospects for improvement. There remains a
general consensus that carcinogens fall into two main
categories - agents that are either genotoxic or non-
genotoxic - and currently both are tested in laboratory
animals. This is unavoidable, partly because of the lack of
adequate substitutes and especially because of pressures from
regulatory bodies. Ironically, these same pressures have led to
a situation in which the quality of the result can be compro-
mised. Essentially, the problem has arisen through expecta-
tions that have been placed upon animal tests, giving them
the status of a bioassay, and over a period this had led to
unjustified assumptions concerning the meaning of the
results. It has always been evident to the critical observer
that the animal can contribute much towards an understan-
ding of mechanisms of carcinogenesis, a point made clearly
by one of the contributors, but that it can never be a truly
adequate bioassay because of the variable natures of both the
initiating stimuli and the ultimate biological end points. This
book takes a hard look at the realities of the use of animals
in carcinogenicity testing. In doing so it questions the validity
of the conclusions, defines the problems and seeks ways
towards improvements for the future.
Essentially, the book can be divided into four sections,
dealing with the issues involved, how study design can be
improved, decision-making and indications of the way for-
ward. They are variable in quality, but all contribute
valuable and interesting insights into an area where science is
primarily driven by economic and regulatory pressures. The
first section opens with a general review of mechanisms in
carcinogenesis, which presents the background for the conc-
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genotoxic agents in which in vitro and in vivo studies comple-
ment each other, whereas for non-genotoxic agents no well-
validated methods are available, a reflection of the relatively
less well-understood mechanisms of action. Moreover, the
relevance of such tests is questioned when animal tests are
used for non-genotoxic agents, since in the majority of cases
the doses required to elicit cancer are far higher than those
encountered in human exposure. In subsequent chapters the
validity of the rodent model for carcinogenicity testing is
questioned in almost all of its aspects. The use of the max-
imum tolerated dose, lifetime vs fixed-duration studies, the
importance or otherwise of using more than one animal
species and the differing spectrum of tumour induction in
man and rodents are all matters given serious consideration.
There is a call for the development of protocols in which
more use is made of current knowledge of mechanisms, for
tests to take account of plasma concentrations and doses at
the site of delivery to the target and for protocols to be
tailored more specifically to the compounds under test. Other
issues raised are, for example, whether prediction based on
current knowledge could even substitute for carcinogenicity
testing in certain cases and whether it makes sense to attempt
to cure cancer with cancer-causing agents.
Over several decades the rodent test has been compromised
by a gradual increase in rat body weight, a shortening of
lifespan and an increased incidence of spontaneous tumours.
This had led to a move towards fixed-duration studies as
opposed to lifetime studies. Examples of these problems are
clearly documented and ways of dealing with them, including
dietary optimisation, are discussed. Other areas considered
are the use of multistrains and the value of pooled control
data and three chapters are devoted to the importance of
pharmacokinetics.
In the chapters on decision-making, difficulties in the
prediction of non-genotoxic carcinogenesis are considered.
Recommendations for the use of other biological data includ-
ing genotoxicity tests, species differences in metabolism and
exposure data for animals as well as man are made with a
view to gaining a more realistic assessment of the hazards
involved in the use of a particular compound and to avoid
sole reliance upon carcinogenicity tests. Case studies included
in this section illustrate some of these issues.
In the way forward, the plea is for a more rational app-
roach in study design that will take account of all biological
information that is relevant to the compounds under test, the
classification of agents to give a tiered approach towards
assessment that would be internationally acceptable, dietary
improvements, a move away from the standardised sub-
lifetime studies and, above all, the recognition that the rodent
test is a model system rather than a bioassay that provides
unequivocal answers.
Overall, the discourse in this volume illustrates the
strenuous efforts than have been made to fit a square peg
(the rodent test) into a neat round hole (the demands of the
regulatory bodies). While those involved are conscientiously
picking ways around this 'Catch 22' situation in the interest
of public protection, they find themselves increasingly in
difficulties with a minority of those whom they seek to
protect.
P.J. O'Connor
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